STOCKS TELEGRAPH

Author: Fahim Awan

  • Soligenix (SNGX) Stock Soars Following Promising Trial Results

    Soligenix (SNGX) Stock Soars Following Promising Trial Results

    Following the release of positive trial data, shares of Soligenix, Inc. (NASDAQ: SNGX) saw a significant increase in value. SNGX’s stock was up 95.20% at $2.44 as of the most recent trading. The spike comes after the company revealed that the major effectiveness goals of its Phase 2a proof-of-concept study for SGX945 (dusquetide) in treating Behçet’s disease were met.

    Phase 2a Research Shows Efficacy on Par with Authorized Therapy

    The Phase 3 study of apremilast (Otezla), which supports its marketing approval for oral ulcers in Behçet’s disease, was closely modeled by the Phase 2a open-label experiment. The results of SGX945 were compared to the apremilast and placebo groups of that Phase 3 trial.

    Over the course of four weeks, SGX945 showed improvements in oral pain and ulcer count that were equivalent to those seen with apremilast. Interestingly, effectiveness continued through Weeks 5–8, almost matching continuous apremilast therapy throughout the same time frame, even though SGX945 medication ended at Week 4.

    Sustained Benefits Beyond Treatment Period

    Using the same primary endpoint—area under the curve (AUC) for mean ulcer count over time—SGX945 achieved a 40% improvement versus placebo, compared to 37% for apremilast. At Week 8, four weeks post-treatment, SGX945 maintained a 32% improvement, while apremilast, administered through Week 12, recorded a 41% improvement.

    Seven of eight patients reported symptom relief, including shorter ulcer duration, fewer occurrences, and reduced pain. A skin ulcer in one patient, typically difficult to treat, resolved during the study. SGX945 was well tolerated, with no treatment-related adverse events reported.

    Future Development and Market Potential

    Soligenix plans to reformulate SGX945 for home-based administration via subcutaneous injection, potentially supporting chronic or maintenance use. SNGX is to progress the development of dusquetide for Behçet’s Disease and other inflammatory illnesses linked to the innate immune system.

    Behçet’s disease is a major unmet medical need, with an estimated 18,000 people in the United States, 50,000 in Europe, 350,000 in Turkey, and up to 1 million worldwide. SGX945 may become a competitive option to existing treatments given the effectiveness, longevity, and tolerability seen, especially for individuals with severe or chronic ulcers.

  • Alignment Healthcare (ALHC) Stock Surges After-Hours On Strong Earnings

    Alignment Healthcare (ALHC) Stock Surges After-Hours On Strong Earnings

    Wednesday saw a notable market surge for Alignment Healthcare, Inc. (NASDAQ: ALHC), which closed at $13.00 after rising 10.36% during the regular session. The momentum carried over into the extended session, as shares increased by 18.77% to $15.44. The company’s second-quarter results announcement, which highlighted strong growth in both financial performance and membership, was followed by the gains.

    Strong Membership Development and Revenue Growth

    Approximately 223,700 people were enrolled in Alignment Healthcare’s health plan during the quarter, a 27.8% increase from the previous year. The total income increased by 49.0% from the previous year to $1,015.3 million. The firm reported a net income of $15.7 million, an adjusted EBITDA of $45.9 million, and a medical benefits ratio of 86.7% based on adjusted gross profit.

    Creative Care Initiatives

    Through initiatives like Care Anywhere, which served 11,500 members in 2024—a 35% increase from 2023—Healthcare continues to lead the way in innovative elder care models. With the help of a virtual care center open around-the-clock, this program expands access to both in-home and virtual care.

    In 2024, the company’s ACCESS On-Demand Concierge Card saw 3.1 million transactions, a 95% increase over the previous year. The number of eligible users increased from 97,000 to 151,000, increasing the usage of over-the-counter and supermarket health benefits.

    Enhanced Preventive Care and Decreased Hospitalization

    The company’s focus on preventative care has produced quantifiable outcomes. In 2024, skilled nursing facility admissions were 47% lower than the 2019 Medicare fee-for-service guideline, while hospitalization rates decreased to 149 per 1,000 members, a 4.5% decrease from 2023. Furthermore, the caregiver benefit program supported 117,000 participants, up from 63,000 the previous year, and increased eligibility by 86%.

    Enhancements in Care Driven by Technology

    Alignment’s in-house AVA® technology platform keeps improving the way treatment is provided. Health risk assessments, mental health navigation, in-network scheduling, and virtual care coordination have all improved as a result of new integrations. The company’s dedication to efficiency and customer-centered service was strengthened by these innovations, which together cut administrative wait times by 45 minutes per member.

    Alignment Healthcare maintains its position as a leader in Medicare Advantage by achieving impressive financial outcomes, creative initiatives, and technological advancements that raise the bar for member happiness, quality, and accessibility.

  • BioNexus (BGLC) Shares Surge On Fidelion Alliance For Liquid Biopsy Technology

    BioNexus (BGLC) Shares Surge On Fidelion Alliance For Liquid Biopsy Technology

    BioNexus Gene Lab Corp. (NASDAQ: BGLC) witnessed a sharp market rally after announcing a major partnership. As of the latest session, BGLC stock surged 45.74%, trading at $6.50. The surge follows the company’s signing of a term sheet with Singapore-based Fidelion Diagnostics Pte Ltd for a cross-equity, strategic collaboration. Both parties describe this as a “DeepSeek-class leap” in liquid biopsy cancer monitoring and AI-powered biotechnology—aligned with BioNexus’ goal of advancing tumor-naïve oncology solutions.

    Equity Partnership and Commercial Rights in Southeast Asia

    Under the agreement, BioNexus will acquire a strategic equity position in Fidelion, gaining exclusive commercial rights to the VitaGuard minimal-residual-disease (MRD) platform throughout Southeast Asia (ASEAN). In return, Fidelion will receive both an equity investment and a license fee from BioNexus. The deal remains subject to final definitive agreements.

    VitaGuard: Transforming Cancer Detection and Cost Efficiency

    Liquid biopsy technology, which detects fragments of tumor DNA (ctDNA) through a simple blood draw, enables earlier detection of cancer recurrence—often months before visible on CT scans. Unlike conventional methods requiring invasive tissue biopsies, VitaGuard offers a less invasive, lower-cost alternative. Labs can conduct VitaGuard tests for under USD $300, compared to approximately USD $3,000 for current U.S. options.

    VitaGuard’s tumor-naïve design sets it apart from most ctDNA tests, which typically require prior tumor sequencing. Similar to advanced facial-recognition technology, VitaGuard can identify cancer at its earliest stages without needing prior genetic data.

    China-Biotech Momentum and Regional Growth Outlook

    Developed by Tongshu Gene Biotechnology Co., Limited in China, VitaGuard is already commercialized there, with Fidelion serving as the licensing platform for global expansion. The agreement coincides with a surge in China’s biopharma sector, marked by significant licensing deals, venture capital inflows, and IPO activity over the past 18 months—trends analysts term the “China-Biotech Wave.”

    With Southeast Asia projected to see over 2.4 million new cancer cases annually by 2030, the sub-USD $300 cost point positions VitaGuard as a transformative, recurring revenue opportunity. By pairing BioNexus’ commercial infrastructure with Fidelion’s technology, the alliance aims to deliver next-generation oncology solutions to approximately 680 million people across ASEAN, marking a pivotal advancement in precision cancer care.

  • Excelerate Energy (EE) Stock Jumped In Extended Session On Raised Guidance

    Excelerate Energy (EE) Stock Jumped In Extended Session On Raised Guidance

    Excelerate Energy, Inc. (NYSE: EE) saw a significant increase during Tuesday’s extended session, trading at $26.66 after climbing 7.98%. The spike occurred after the company increased its full-year 2025 Adjusted EBITDA estimate and disclosed pro forma financial figures pertaining to its recently acquired Jamaican assets.

    Upgraded Financial Outlook Following Acquisition

    Excelerate Energy increased the range of projected Adjusted EBITDA for the entire year 2025 to $420–$440 million. The revised prediction came after it successfully acquired the integrated liquefied natural gas (LNG) and power platform in Jamaica from New Fortress Energy Inc. in May 2025. Additionally, the business submitted a Form 8-K/A that included pro forma financial data, including past performance from the businesses it had bought.

    Pro Forma Results and Integration Progress

    Based on predetermined procedures and assumptions, the pro forma data includes cost allocations unique to the Seller’s activities in Jamaica. The pro forma Adjusted EBITDA for the quarter ending March 31, 2025, and the entire year 2024, after accounting for certain Seller-specific adjustments, stayed in line with Excelerate Energy’s management projections. Management confirmed that integration efforts are on track, with operational performance meeting or surpassing reliability targets.

    Strategic Expansion of LNG Infrastructure

    The Jamaica acquisition is a key milestone in Excelerate Energy’s strategy to establish itself as a provider of essential last-mile energy infrastructure. The assets acquired include the Montego Bay LNG Terminal, the Old Harbour LNG Terminal, and the Clarendon combined heat and power plant. To finance the deal, Excelerate successfully secured approximately $1.0 billion through equity and debt transactions.

    Successful Capital Raising Initiatives

    Excelerate raised $212 million in total revenues, including the greenshoe option, via the sale of eight million shares of Class A common stock at a price of $26.50 each in the second quarter of 2025. Additionally, the company strengthened its balance sheet to enable acquisition finance and operational expansion by closing a $800 million issue of senior unsecured notes with an 8.000% interest rate that was due in 2030.

  • After-Market Rally: Rocky Brands (RCKY) Stock Climbs On Solid Earnings

    After-Market Rally: Rocky Brands (RCKY) Stock Climbs On Solid Earnings

    Rocky Brands, Inc. (NASDAQ: RCKY) shares surged when the company’s second-quarter 2025 financial results were made public. After-market activity saw the stock rise 30.55%, at $30.00.

    Compared to the same period previous year, net revenues for the quarter ending June 30, 2025, grew 7.5% to $105.6 million. Compared to a net loss of $1.2 million, or $0.17 per diluted share, in the previous year quarter, net income increased to $3.6 million, or $0.48 per diluted share.

    Performance in Operations and Brand Momentum

    Rocky Brands attributed its success to excellent execution, which was fueled by the robustness of its production network and diverse brand portfolio. With increased demand in both wholesale and e-commerce channels, XTRATUF drove the rise, while Muck had its most robust quarterly gain in recent memory.

    Significant profitability benefits were achieved as a consequence of a 230-basis point rise in gross margins brought about by strategic supply chain agility and advantageous pricing.

    Updates on the Financial Situation and Inventory

    As of June 30, 2025, Rocky Brands reported inventory of $186.8 million, up 12.1% from December 31, 2024, and 6.8% from the year prior. Net of $2.0 million in unamortized issuance expenditures, the total debt was $132.5 million, down 13.1% from June 30, 2024, but up 2.9% from the end of 2024.

    The debt structure included borrowings of $103.6 million under the senior secured asset-backed credit facility and a $30.9 million senior term loan. Cash and cash equivalents totaled $2.8 million, a decrease from $4.1 million during the same period last year.

    Prospects and Strategic Projects

    Rocky Brands has the confidence it needs to take on the remainder of the year thanks to strong momentum and strong wholesale reservations for the second half of 2025. RCKY uses strategies like using its production facilities in Puerto Rico and the Dominican Republic to mitigate the effects of tariffs and maintains a cautious sense of optimism in the face of broader market uncertainty.

    Management emphasized that the business is in a strong position to sustain both short-term resilience and long-term development, despite the fact that it is still challenging to predict client demand.

  • AstraZeneca (AZN) Shares Climb In Pre-Market On Positive FDA Progress

    AstraZeneca (AZN) Shares Climb In Pre-Market On Positive FDA Progress

    Following important regulatory news, AstraZeneca PLC (NASDAQ: AZN) started to exhibit upward momentum in pre-market trading. AZN shares were worth $74.36 as of the most recent pre-market check, which is a 3.52% increase.

    The surge comes after the company announced that its supplemental biologics license application (sBLA) for IMFINZI (durvalumab) was accepted by the U.S. Food and Drug Administration (FDA) and that it was given priority review for the treatment of patients with gastric and gastroesophageal junction (GEJ) cancers that are resectable, early-stage, and locally advanced (Stages II, III, IVA).

    FDA Designation of Breakthrough Therapy and Priority Review

    Therapies that have the potential to significantly enhance safety, effectiveness, or patient outcomes above current therapy alternatives are given Priority Review by the FDA. The fourth quarter of 2025 is the target date for the regulatory decision under the Prescription Drug User Fee Act (PDUFA).

    In order to meet important unmet needs in the treatment of gastric cancer, IMFINZI has also obtained Breakthrough Therapy Designation (BTD) for this indication, accelerating the development and review process.

    Results of Clinical Trials Show Great Efficacy

    Data from the MATTERHORN Phase III study, which was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine, provide support for the sBLA filing. The trial assessed an IMFINZI and chemotherapy perioperative regimen before surgery, followed by IMFINZI treatment after surgery.

    When compared to chemotherapy alone, the risk of illness progression, recurrence, or mortality was reduced by 29%, according to interim analysis. With 24-month EFS rates of 67.4% vs 58.5%, respectively, the IMFINZI arm had not yet achieved the estimated median event-free survival (EFS), but the control arm had done so after 32.8 months.

    International Regulatory Reviews Are In Progress

    One of the primary causes of cancer death and the fifth most frequent cancer globally is still gastric cancer. An estimated 6,500 Americans had treatment for locally progressed or early-stage gastric or GEJ malignancies in 2024. IMFINZI is the only immunotherapy that exhibits a statistically significant survival advantage in this context, according to the positive results.

    Potentially opening the door to a new standard of care in the treatment of stomach cancer, regulatory applications for the medication are also being reviewed in the European Union, Japan, and other international markets.

  • Extended Session Boost For Scinai Immunotherapeutics (SCNI) Stock

    Extended Session Boost For Scinai Immunotherapeutics (SCNI) Stock

    Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) experienced a significant extended-session rally after highlighting recognition for its breakthrough science. SCNI stock advanced 14.59% to $2.35, following the announcement that one of its key collaborators earned a distinguished award in dermatology research.

    Prestigious Award for Pioneering Pemphigus Research

    Scinai Immunotherapeutics disclosed that Dr. Roberta Lotti, a lead scientist at Pincell Srl, received the esteemed “Oscar of Italian Dermatology” from SIDeMaST, the Italian Society of Dermatology and Venereology.

    The honor, awarded in the Immunopathology and Cutaneous Allergies category, recognized her groundbreaking study, “Blocking Soluble Fas Ligand Ameliorates Pemphigus: PC111 Efficacy in Ex-Vivo Human Pemphigus Models.”

    The research focuses on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. Scinai holds a strategic option agreement to acquire Pincell, the biotech company developing this innovative treatment.

    PC111: A Novel Approach to Severe Autoimmune Skin Diseases

    PC111 targets the soluble form of Fas Ligand (sFasL), a critical driver of Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN)—serious autoimmune and drug-induced blistering disorders with high morbidity and mortality rates.

    Earlier studies by Pincell demonstrated that soluble FasL triggers keratinocyte apoptosis leading to acantholysis. Dr. Lotti’s award-winning paper confirmed PC111’s mechanism of action in human pemphigus models, showing that it inhibits blister formation by preventing apoptosis—representing a differentiated, non-immunosuppressive approach to treatment.

    Potential for Clinical Use and Strategic Consequences for Scinai

    The local method of action of PC111 tackles the disease process directly, potentially decreasing long-term adverse effects, in contrast to traditional medicines that rely on systemic immunosuppression. Instead of only managing symptoms, this breakthrough represents a step toward disease-modifying treatments.

    The acknowledgement supports Scinai’s plan to safeguard Pincell’s pipeline for autoimmune dermatology. PC111 is positioned as a high-value asset in Scinai’s immunology portfolio due to its promising profile, faster regulatory routes, and possible orphan medication classification.

    Industry Acknowledgment

    The price was awarded during the XIV International Congress of Dermatology in Rome last month. SIDeMaST’s “Oscar of Italian Dermatology,” is one of the most prestigious awards in the area, which highlights the importance of Dr. Lotti’s work from a scientific and clinical standpoint.

    Scinai keeps developing PC111 in an effort to make it a game-changing treatment for those with severe, uncommon dermatological conditions.

  • Chart Industries (GTLS) Stock Surges In After-Market Trading

    Chart Industries (GTLS) Stock Surges In After-Market Trading

    Following news of a possible takeover deal, Chart Industries, Inc.’s (NYSE: GTLS) stock saw a sharp increase on Monday. After-hours trading saw GTLS shares rise 18.28% to $203.02.

    According to the Financial Times, the rise coincides with Baker Hughes, a major player in the oil and gas equipment industry, apparently nearing completion of a $13.6 billion cash agreement to buy Chart Industries. However, the deal is still being negotiated and is not yet complete, the magazine stated.

    Baker Hughes Edges Out Rival Bid

    Baker Hughes’ reportedly proposed deal surpasses a previous $19 billion all-stock merger agreement between Chart Industries and Flowserve, which was announced in June but has since been terminated. The proposal from Baker Hughes caused Chart’s board to reevaluate its previous commitment to Flowserve by providing an equity valuation of $210 per share, which was 22% more than Chart’s market price.

    The purchase is in line with Baker Hughes’ overarching plan to increase its presence in the LNG and natural gas markets by diversifying its portfolio of energy and industrial technologies.

    Part of a Larger Energy Sector Consolidation

    The possible takeover comes amid an ongoing wave of consolidation in the U.S. energy industry. In 2023 alone, mergers and acquisitions in the sector reached $250 billion, although activity slowed toward the end of the year.

    As of Monday’s close, Chart Industries maintained a market capitalization of $7.71 billion. The company is recognized for manufacturing advanced industrial equipment, including valves and measurement systems for handling gas and liquid molecules.

    LNG Alliance Selects Chart’s IPSMR Technology

    In a separate development this month, Chart Industries secured a significant contract with LNG Alliance Pte Ltd for its Amigo LNG export facility in Guaymas, Sonora, Mexico. With a 7.8 million tonnes per annum (MTPA) capacity, the plant will use Chart’s modular liquefaction system and IPSMR (Integrated Pre-cooled Single Mixed Refrigerant) process technology.

    By enabling operators to customize liquefaction systems to site-specific conditions, this technique aims to maximize efficiency by guaranteeing the optimal ratio of cold box capacity to compression power. It is anticipated that this capacity would reduce expenses for LNG Alliance while improving operational performance.

  • After-Hour Rally: Sarepta (SRPT) Gains Nearly 50% After FDA Greenlights

    After-Hour Rally: Sarepta (SRPT) Gains Nearly 50% After FDA Greenlights

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had a significant increase in the value of its shares on Monday, rising 48.77% in after-hours trading to $20.62 after closing at $13.86 in the regular session, when it had gained 16.18%.

    Following the FDA’s decision to let Sarepta to lift its voluntary halt on shipments of ELEVIDYS (delandistrogene moxeparvovec), their gene therapy for ambulatory individuals with Duchenne muscular dystrophy, the rally was held. The only FDA-approved gene treatment for this uncommon, progressive, and potentially fatal illness is still ELEVIDYS.

    FDA Review and Resumption of Supply

    Sarepta had voluntarily paused shipments of ELEVIDYS last week at the FDA’s suggestion to allow a thorough safety review. The agency completed its assessment rapidly and recommended the resumption of supply for ambulatory patients.

    Shipments to treatment centers are set to recommence immediately. Discussions regarding risk mitigation for non-ambulatory patients are ongoing, with shipments for this group remaining paused pending further agreement on safety protocols.

    Safety Evaluation and Brazilian Case Review

    A case involving the death of an 8-year-old kid in Brazil was investigated as part of the FDA’s safety evaluation. The FDA affirmed the Brazilian health authorities’ conclusion that ELEVIDYS was not likely to be connected to the occurrence. The regulator allowed Sarepta to restart shipments for the approved patient population after concluding that the therapy was not linked to the death.

    Arrowhead Pharmaceuticals’s Significant Accomplishment

    Arrowhead Pharmaceuticals said in a related release that Sarepta has made a milestone payment of $100 million. In its Phase 1/2 clinical study of ARO-DM1, an experimental RNA interference (RNAi) treatment for type 1 myotonic dystrophy (DM1), the most prevalent adult-onset muscular dystrophy, Arrowhead met the first of two predetermined enrollment objectives, which led to the payment.

    Authorization to escalate dosing has also been granted. Arrowhead anticipates reaching the second enrollment target by late 2025, which would result in an additional $200 million milestone payment from Sarepta.

  • Market Confidence Grows As CEA Industries (VAPE) Strengthens BNB Exposure

    Market Confidence Grows As CEA Industries (VAPE) Strengthens BNB Exposure

    CEA Industries Inc. (NASDAQ: VAPE) experienced an extraordinary rally on Monday, with shares skyrocketing 587.94% to $61.06 following the announcement of a landmark equity development.

    VAPE confirmed the pricing of an oversubscribed and upsized above‑the‑market PIPE financing in partnership with 10X Capital and YZi Labs. This move positions CEA Industries to become the largest publicly traded BNB Treasury Company in the United States.

    Expanding Institutional Access to BNB

    The PIPE marks a significant step in institutionalizing access to $BNB—one of the world’s top four digital asset tokens with a market capitalization exceeding $100 billion. CEA Industries will begin deploying the raised capital to acquire BNB, providing both institutional and retail investors an entry point into the BNB Chain ecosystem.

    This blockchain platform supports millions of global users and decentralized applications, making it one of the most actively utilized Layer‑1 networks.

    Leadership Strengthened by Industry Veterans

    Upon closing, CEA’s executive team will integrate seasoned leaders including incoming CEO David Namdar, Co‑Founder of Galaxy Digital; CIO Russell Read, former CIO of CalPERS and Deutsche Bank Asset Management; and Saad Naja, former director at Kraken. Their combined expertise is expected to guide the treasury’s growth strategy and enhance institutional credibility.

    Strong Investor Participation Signals Market Confidence

    The financing attracted more than 140 subscribers, led by major institutional and crypto‑native investors such as YZi Labs, Pantera Capital, Arche Capital, Blockchain.com, and Arrington Capital. Notable individual investors include Olaf Carlson Wee and Rajeev Misra’s family office.

    CEA intends to grow its initial BNB position significantly over the next 12–24 months through a structured capital markets program, while exploring staking and lending opportunities within the Binance ecosystem under a prudent risk framework. With its Nasdaq‑listed vehicle, CEA Industries is bridging the gap between digital assets and mainstream capital markets.

    Unlike Bitcoin‑centric treasury firms, this initiative offers direct exposure to the BNB Chain—a rapidly growing network with robust DeFi, NFT, and Web3 activity. The PIPE is expected to close by July 31, 2025, after which the updated treasury strategy will take effect.